Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-023-02448-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Zhimin Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. Hauptthemen laut MEDLINE: Sarcopenia, Cisplatin, Leukopenia, Deoxycytidine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Six Talent Peaks Project in Jiangsu Province, Project supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China, Post-doctoral Research Funding Project in Jiangsu Province.
Abstract (Originalsprache)
Background
In the era of combination therapy, there has been limited research on body composition. Specific body composition, such as sarcopenia, possesses the potential to serve as a predictive biomarker for toxic effects and clinical response in patients with urothelial carcinoma (UC) undergoing tislelizumab combined with gemcitabine and cisplatin (T + GC). Materials and Methods A total of 112 UC patients who received T + GC were selected at the Affiliated Hospital of Xuzhou Medical University from April 2020 to January 2023. Baseline patient characteristics and detailed hematological parameters were collected using the electronic medical system and laboratory examinations. The computed tomography images of patients were analyzed to calculate psoas muscle mass index (PMI). We evaluated the association between sarcopenia (PMI < 4.5 cm 2 /m 2 in men; PMI < 3.3 cm 2 /m 2 in women) and both hematological toxicity and tumor response.
Results
Overall, of the 112 patients (65.2% male, median age 56 years), 43 (38.4%) were defined as sarcopenia. Patients with sarcopenia were notably older ( p = 0.037), more likely to have hypertension ( p = 0.009), and had poorer ECOG-PS ( p = 0.027). Patients with sarcopenia were more likely to develop leukopenia (OR 2.969, 95% CI 1.028–8.575, p = 0.044) after receiving at least two cycles of T + GC. However, these significant differences were not observed in thrombocytopenia and anemia. There were no significant differences in the tumor response and grade 3–4 hematological toxicity between patients with sarcopenia and those without sarcopenia.
Conclusions
Patients with sarcopenia were more likely to develop leukopenia after receiving T + GC. There were no notable alterations observed in relation to anemia or thrombocytopenia. No significant difference was found between the sarcopenia group and non-sarcopenia group in terms of tumor response and grade 3–4 hematological toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China.
- Graduate School of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China.
- Suining People's Hospital, Xuzhou, 221000, People's Republic of China.
- Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. qinieys@163.com.
- Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, People's Republic of China. justinlee719@163.com.
Förderung
- Six Talent Peaks Project in Jiangsu Province
- Project supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China
- Post-doctoral Research Funding Project in Jiangsu Province
- Second Round of Xuzhou Medical Leading Talents Training Project
- The Science and Technology Planning Project of Traditional Chinese Medicine of Jiangsu
- Practice Innovation Program of Jiangsu Province
- Postgraduate Research and Practice Innovation Project of Jiangsu Province
Zitieren
APA
Gao, Z., Pang, Y., Qin, X., Li, G., Wang, Z., Zhang, L., Wang, J., Qi, N., & Li, H. (2024). Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-023-02448-1
Vancouver
Gao Z, Pang Y, Qin X, Li G, Wang Z, Zhang L, et al. Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-023-02448-1
BibTeX
@article{Gao2024,
author = {Gao, Zhimin and Pang, Yubin and Qin, Xu and Li, Gang and Wang, Zewei and Zhang, Lei and Wang, Junqi and Qi, Nienie and Li, Hailong},
title = {Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-023-02448-1}
}
EUVIMED